{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:56:34Z","timestamp":1791428194107,"version":"4.3.3"},"reference-count":19,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Technology &amp; Therapeutics"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:p>\n                    Continuous glucose monitoring (CGM) is indicated in poorly controlled insulin-treated patients with type 2 diabetes (T2D) to improve glycemic control and reduce the risk of hypoglycemia, but the benefits of CGM for lower risk patients have not been well studied. Among 17,422 insulin-treated patients with T2D with hemoglobin A1c (HbA1c) &lt;8% and no recent severe hypoglycemia (based on emergency room visits or hospitalizations), CGM initiation occurred in 149 patients (17,273 noninitiators served as reference). Changes in HbA1c and severe hypoglycemia rates for the 12 months before and after CGM initiation were calculated. CGM initiation was associated with decreased HbA1c (\u22120.06%), whereas noninitiation was associated with increased HbA1c (+0.32%); a weighted adjusted difference-in-difference model of change in HbA1c yielded a net benefit of \u22120.30%; 95% CI \u22120.50%, \u22120.10%;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2009=\u20090.004). No significant differences were observed for severe hypoglycemia. CGM may be useful in preventing glycemic deterioration in well-controlled patients with insulin-treated T2D.\n                  <\/jats:p>","DOI":"10.1089\/dia.2021.0450","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T16:54:01Z","timestamp":1643734441000},"page":"332-337","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":13,"title":["Continuous Glucose Monitor Use Prevents Glycemic Deterioration in Insulin-Treated Patients with Type 2 Diabetes"],"prefix":"10.1177","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5527-316X","authenticated-orcid":false,"given":"Andrew J.","family":"Karter","sequence":"first","affiliation":[{"name":"Kaiser Permanente\u2014Division of Research, Oakland, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa M.","family":"Parker","sequence":"additional","affiliation":[{"name":"Kaiser Permanente\u2014Division of Research, Oakland, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard H.","family":"Moffet","sequence":"additional","affiliation":[{"name":"Kaiser Permanente\u2014Division of Research, Oakland, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa K.","family":"Gilliam","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Northern California, South San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Dlott","sequence":"additional","affiliation":[{"name":"The Permanente Medical Group, Martinez, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,5,10]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.7326\/M16-2855"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.7444"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.6530"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.16153"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.2016.1260466"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.7819"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-200009000-00011"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwq439"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e3181a663cc"},{"key":"e_1_3_6_11_2","first-page":"250","article-title":"Addressing extreme propensity scores via the overlap weights","volume":"188","author":"Li F","year":"2019","unstructured":"Li F, , Thomas LE, , Li F: Addressing extreme propensity scores via the overlap weights. Am J Epidemiol, 2019; 188:250\u2013257.","journal-title":"Am J Epidemiol"},{"key":"e_1_3_6_12_2","first-page":"145","article-title":"The statistical power of abnormal-social psychological research: a review","volume":"65","author":"Cohen JC","year":"1962","unstructured":"Cohen JC: The statistical power of abnormal-social psychological research: a review. J Abnorm Psychol, 1962; 65:145\u2013153.","journal-title":"J Abnorm Psychol"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/00273171.2011.568786"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-199901000-00008"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jspi.2004.06.060"},{"key":"e_1_3_6_16_2","unstructured":"Wang Y Petersen ML Bangsberg D et al.: \u201cDiagnosing bias in the inverse probability of treatment weighted estimator resulting from violation of experimental treatment assignment\u201d (September 2006). U.C. Berkeley division of biostatistics working paper series. Working Paper 211. https:\/\/biostats.bepress.com\/ucbbiostat\/paper211 (accessed February14 2022)."},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2016.8648"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2011.11.036"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(92)90133-8"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2017.3844"}],"container-title":["Diabetes Technology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/dia.2021.0450","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2021.0450","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2021.0450","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:13:27Z","timestamp":1777400007000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/dia.2021.0450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1089\/dia.2021.0450"],"URL":"https:\/\/doi.org\/10.1089\/dia.2021.0450","relation":{},"ISSN":["1520-9156","1557-8593"],"issn-type":[{"value":"1520-9156","type":"print"},{"value":"1557-8593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5]]}}}